Vistagen Therapeutics, Inc. (VTGN)
0.2434
+0.01
(+3.35%)
USD |
NASDAQ |
Sep 10, 16:00
Vistagen Therapeutics Profit Margin (Quarterly) : -882.8% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -882.8% |
| March 31, 2026 | -3.50K% |
| December 31, 2025 | -6.24K% |
| September 30, 2025 | -7.53K% |
| June 30, 2025 | -6.19K% |
| December 31, 2024 | -6.02K% |
| September 30, 2024 | -7.08K% |
| June 30, 2024 | -12.78K% |
| March 31, 2024 | -4.83K% |
| December 31, 2023 | -1.54K% |
| September 30, 2023 | -2.37K% |
| June 30, 2023 | -3.89K% |
| March 31, 2023 | -6.96K% |
| December 31, 2022 | -5.43K% |
| September 30, 2022 | |
| June 30, 2022 | -6.38K% |
| March 31, 2022 | -42.79K% |
| December 31, 2021 | -2.94K% |
| September 30, 2021 | -3.57K% |
| June 30, 2021 | -2.19K% |
| March 31, 2021 | -1.41K% |
| December 31, 2020 | -1.69K% |
| September 30, 2020 | -987.4% |
| June 30, 2020 | |
| March 31, 2020 |
| Date | Value |
|---|---|
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | -211.1% |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 10.23% |
| Alnylam Pharmaceuticals, Inc. | 12.74% |
| Anika Therapeutics, Inc. | 10.15% |
| Savara, Inc. | -- |
| Vericel Corp. | 2.85% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -144.5% |
| Return on Assets | -113.0% |
| Return on Invested Capital | -140.0% |
| Gross Profit Margin (Quarterly) | 86.65% |
| Operating Margin (Quarterly) | -904.3% |
| Return on Net Operating Assets | -4.83K% |